Vivani Medical is developing GLP-1 subdermal implants that aim to provide a consistent therapeutic dose for six months, and ...

Adapting to uncertainty over product review timelines at FDA could complicate M&A for pharma buyers and sellers, especially ...

California's AB 824 law has important implications for branded and generics companies involved in settlement agreements. AB ...

Social proof—seeing peers safely participate—reduces fear and builds trust in clinical trials. Sharing real stories and ...

Improvements in diagnostics for the early detection of Alzheimer's disease have the potential to transform patient care and new drug development, writes Mike Banville, CEO and President at ALZpath.

They say the mark of intelligence is making the complex simple. By that standard, navigating early commercialization in the pharmaceutical industry is one of the toughest challenges, especially for ...

Electronic Clinical Outcome Assessments (eCOAs) have advanced considerably, yet persistent myths still prevent clinical teams from leveraging their full value. As regulatory expectations evolve and ...

There are lots of reasons why physicians and patients (and payers) might prefer one drug over another for the treatment of a given disease. Efficacy and safety are paramount, of course, but there are ...

Multiregional clinical trials (MRCTs) have become a cornerstone of global drug development, enabling simultaneous evaluation of therapies while adhering to rigorous standards required for regulatory ...

On this week's episode of the Business of Biotech, Dr. Mark Eisner, EVP and Chief Medical Officer at Vir Biotechnology, talks about the company's post-COVID pivot into infectious diseases (Hepatitis ...